Tilarginine does not reduce the risk of mortality for patients with acute myocardial infarction (MI) and cardiogenic shock

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1581, 2007-01, pp. : 10-10

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Treatment Strategies in Cardiogenic Shock Complicating Acute Myocardial Infarction

By  

Heart Drug, Vol. 1, Iss. 3, 2001-07 ,pp. : 176-181

Karger

Access to resources Recommend Favorite

Patients with acute myocardial infarction (MI) benefit from early treatment with statins

By  

Inpharma, Vol. 1, Iss. 1289, 2001-01 ,pp. : 19-19

Adis International

Access to resources Recommend Favorite

Imatinib/sorafenib: Fatal myocardial infarction with cardiogenic shock: case report

By  

Reactions Weekly, Vol. 1, Iss. 1353, 2011-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

Inappropriate -blocker prescribing after acute myocardial infarction (MI) is associated with greater mortality than appropriate prescribing

By  

Inpharma, Vol. 1, Iss. 1511, 2005-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite

Loratadine improves the ischaemic parameters of an exercise stress test in patients with acute myocardial infarction (MI)

By  

Inpharma, Vol. 1, Iss. 1475, 2005-01 ,pp. : 19-19

Adis International

Access to resources Recommend Favorite